Literature DB >> 29076185

Test-compatible confidence intervals for adaptive two-stage single-arm designs with binary endpoint.

Kevin Kunzmann1, Meinhard Kieser1.   

Abstract

Inference after two-stage single-arm designs with binary endpoint is challenging due to the nonunique ordering of the sampling space in multistage designs. We illustrate the problem of specifying test-compatible confidence intervals for designs with nonconstant second-stage sample size and present two approaches that guarantee confidence intervals consistent with the test decision. Firstly, we extend the well-known Clopper-Pearson approach of inverting a family of two-sided hypothesis tests from the group-sequential case to designs with fully adaptive sample size. Test compatibility is achieved by using a sample space ordering that is derived from a test-compatible estimator. The resulting confidence intervals tend to be conservative but assure the nominal coverage probability. In order to assess the possibility of further improving these confidence intervals, we pursue a direct optimization approach minimizing the mean width of the confidence intervals. While the latter approach produces more stable coverage probabilities, it is also slightly anti-conservative and yields only negligible improvements in mean width. We conclude that the Clopper-Pearson-type confidence intervals based on a test-compatible estimator are the best choice if the nominal coverage probability is not to be undershot and compatibility of test decision and confidence interval is to be preserved.
© 2017 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Keywords:  adaptive designs; binary endpoint; confidence interval; two-stage designs

Mesh:

Year:  2017        PMID: 29076185     DOI: 10.1002/bimj.201700018

Source DB:  PubMed          Journal:  Biom J        ISSN: 0323-3847            Impact factor:   2.207


  3 in total

1.  Re-formulating Gehan's design as a flexible two-stage single-arm trial.

Authors:  Michael J Grayling; Adrian P Mander
Journal:  BMC Med Res Methodol       Date:  2019-01-28       Impact factor: 4.615

2.  Neoadjuvant irradiation of extremity soft tissue sarcoma with ions (Extrem-ion): study protocol for a randomized phase II pilot trial.

Authors:  D Brügemann; B Lehner; M Kieser; J Krisam; A Hommertgen; C Jaekel; S B Harrabi; K Herfarth; G Mechtesheimer; O Sedlaczek; G Egerer; A Geisbüsch; M Uhl; J Debus; K Seidensaal
Journal:  BMC Cancer       Date:  2022-05-12       Impact factor: 4.638

3.  Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial.

Authors:  Farastuk Bozorgmehr; Inn Chung; Petros Christopoulos; Johannes Krisam; Marc A Schneider; Lena Brückner; Daniel Wilhelm Mueller; Michael Thomas; Stefan Rieken
Journal:  BMC Cancer       Date:  2020-08-26       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.